Actuate Therapeutics, Inc. announced enrollment of the first patients with first-line advanced pancreatic cancer in a phase 2 study...
Read more
Actuate Therapeutics, Inc. has raised an additional $6.5M in a Series B-3 financing round led by Bios Partners with...
Read more
We are delighted to announce that Actuate Therapeutics is the latest company to join the Kairos portfolio. Founded in...
Read more